Larimar Therapeutics Inc Stock
Larimar Therapeutics Inc Stock price
Key metrics
| Market capitalization | $252.67m |
| Enterprise Value | $54.32m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 1.27 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-73.76m |
| Free Cash Flow (TTM) Free Cash Flow | $-58.79m |
| Cash position | $203.71m |
Is Larimar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Larimar Therapeutics Inc Stock Analysis
Analyst Opinions
11 Analysts have issued a Larimar Therapeutics Inc forecast:
Analyst Opinions
11 Analysts have issued a Larimar Therapeutics Inc forecast:
Financial data from Larimar Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.32 -0.32 |
60%
60%
|
|
| EBITDA | -73 -73 |
94%
94%
|
EBIT (Operating Income) EBIT | -74 -74 |
94%
94%
|
| Net Profit | -65 -65 |
94%
94%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Larimar Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Larimar Therapeutics Inc Stock News
Company Profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
| Head office | United States |
| CEO | Carole Ben-Maimon |
| Employees | 42 |
| Founded | 2005 |
| Website | larimartx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
